54706-99-9
中文名稱
20-去氧巨大戟萜醇
英文名稱
20-DEOXYINGENOL
CAS
54706-99-9
分子式
C20H28O4
分子量
332.43
MOL 文件
54706-99-9.mol
更新日期
2025/01/24 10:07:27
54706-99-9 結(jié)構(gòu)式
基本信息
中文別名
20-去氧巨大戟醇20-去氧巨大戟萜醇
20-脫氧-巨大戟醇
20-脫氧巨大戟萜醇
20-去氧巨大戟醇, >98%
英文別名
20-DEOXYINGENOL20-Deoxyingenol, >98%
20-deoxyingenol 54706-99-9
(1aR,10aα)-1a,2,5,5a,6,9,10,10a-Octahydro-5β,5aβ,6β-trihydroxy-1,1,4,7,9α-pentamethyl-1H-2α,8aα-methanocyclopenta[a]cyclopropa[e]cyclodecen-11-one
1H-2,8a-Methanocyclopenta[a]cyclopropa[e]cyclodecen-11-one, 1a,2,5,5a,6,9,10,10a-octahydro-5,5a,6-trihydroxy-1,1,4,7,9-pentamethyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-
所屬類別
生物化工:植物提取物物理化學(xué)性質(zhì)
熔點208-209℃ (分解)
沸點470.5±45.0 °C(Predicted)
密度1.26±0.1 g/cm3 (20 ºC 760 Torr)
儲存條件-20°C儲存
溶解度DMSO : 50 mg/mL (150.41 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
酸度系數(shù)(pKa)12.21±0.70(Predicted)
形態(tài)粉末
顏色White to off-white
20-去氧巨大戟萜醇價格(試劑級)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-N0866 | 20-去氧巨大戟萜醇 20-Deoxyingenol | 54706-99-9 | 5mg | 1000元 |
2024/11/08 | HY-N0866 | 20-去氧巨大戟萜醇 20-Deoxyingenol | 54706-99-9 | 10mM * 1mLin DMSO | 1100元 |
2024/11/08 | HY-N0866 | 20-去氧巨大戟萜醇 20-Deoxyingenol | 54706-99-9 | 10mg | 1800元 |
常見問題列表
生物活性
20-Deoxyingenol 是一種從 Euphorbia kansui 的根中分離出的二萜。20-Deoxyingenol 可通過促進體外轉(zhuǎn)錄因子 EB (TFEB) 的核易位來促進自噬和溶酶體生物發(fā)生。20-Deoxyingenol 可用于骨關(guān)節(jié)炎 (OA) 的研究。體外研究
20-Deoxyingenol (2.5-10 mM; 24 h) protects chondrocytes against Tert-butyl hydroperoxide solution (TBHP; 100?μM)-induced cell death.
20-Deoxyingenol (5-10 mM) decreases the TBHP-induced upregulation of apoptosis protein cleaved-caspase3 and the senescence protein p16INK4a in chondrocytes.
20-Deoxyingenol (2.5-40 mM; 24 h) has no cytotoxic effect on chondrocytes at the concentration less than 10?mM.
20-Deoxyingenol (10 mM; 24 h) restores autophagy flux in TBHP treated chondrocytes.
20-Deoxyingenol (4-10 mM; 24 h) promotes the nuclear level of TFEB in TBHP treated chondrocytes.
體內(nèi)研究
20-Deoxyingenol (20 mg/kg/d; i.p. for 8 weeks) alleviates the progression of OA in the DMM model in mice.
Animal Model: | 10-week-old C57BL/6 male wild-type (WT) mice with destabilization of the medial meniscus (DMM) |
Dosage: | 20 mg/kg |
Administration: | I.p. one time per day, for eight consecutive weeks |
Result: |
Had a slightly wider joint space and reduced bone density and calcification compared with the DMM group.
Inhibited the decrease in the thickness of hyaline cartilage (HC), and alleviated the disorder and hypertrophy of chondrocytes in the joint tissues of mice after DMM surgery. Had less erosion on the surface of the articular cartilage and more proteoglycan content. Had more positive staining points of LAMP1 and LC3 II, and less cleaved-caspase3 and P16INK4a. Increased the nuclear level of TFEB. |